Inside "Drug Reference":

@CancerQuest on Twitter:

Related to this page:

Was this page helpful? | What did you like most? How can we make it better?

CancerQuest > Drugs > Dasatinib (Sprycel®)

Dasatinib (Sprycel®)

Generic Name: Dasatinib Brand Name(s): Sprycel® IUPAC: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide FDA Approval: yes Manufacturer Link

Usage: Dasatinib is approved for use in treatment of: Chronic, accelerated, myeloid or lymphoid blast phase chronic myeloid leukemia (CML) that is resistant to prior therapy (including imatinib), Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) resistant to prior therapy and Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (Ph+ CP-CML).

Mechanism: Dasatinib (Sprycel®) is a multiple tyrosine kinase inhibitor. Some of its targets are bcr-abl, src, c-kit and epha2.

Side Effects: Side effects include: Fluid retention, Diarrhea, Skin rash, Nausea, Fatigue, Shortness of breath

Contraindications: The most common toxicities observed due to dasatinib treatment are myelosuppression (low blood counts), hemorrhage in the central nervous system or gastrointestinal tract and QT prolongation (increased duration of cardiac ventricular repolarization). There is a potential harm to the fetus in pregnant woman who receive dasatinib, therefore women should avoid becoming pregnant during this treatment and pregnant women should be warned of this risk. Due to possible drug interactions, dasatinib treatment should be avoided or closely monitored in patients receiving CYP3A4 inhibitors or inducers, antacids, proton pump inhibitors or hydrogen antagonists.